Physician profile
Alphonse J Zieman
NPI 1811091531
$3,235.63
in general payments reported to CMS, 2019-2025
32 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $490 · 2021: $1,084 · 2022: $448 · 2023: $194 · 2024: $118 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $705.09 | 2020-2024 | Xarelto |
| Novo Nordisk INC | $429.70 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $354.68 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $216.52 | 2019-2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $189.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $186.61 | 2019-2025 | Breztri |
| Amarin Pharma, INC. | $166.69 | 2019-2023 | |
| Lilly USA, LLC | $95.19 | 2019-2023 | Jardiance |
| Pfizer INC. | $94.43 | 2019-2025 | |
| Allergan, INC. | $90.97 | 2019-2020 | |
| Amgen INC. | $80.33 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.87 | 2019-2022 | |
| Astellas Pharma US INC | $72.07 | 2019-2020 | |
| Abbott Laboratories | $57.07 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.04 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $51.64 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $47.80 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $33.32 | 2021 | |
| Esperion Therapeutics, INC. | $25.42 | 2021 | |
| Dexcom, INC. | $23.14 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $23.10 | 2019 | |
| Mylan Specialty L.P. | $20.51 | 2019 | |
| Upsher-Smith Laboratories LLC | $20.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.30 | 2019 | |
| Corcept Therapeutics | $15.97 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.95 | 2021 | |
| Shire North American Group INC | $14.30 | 2019 | |
| Eisai INC. | $13.21 | 2020 | |
| Horizon Therapeutics Plc | $11.78 | 2021 | |
| Currax Pharmaceuticals LLC | $11.69 | 2022 | |
| Ironwood Pharmaceuticals, INC | $11.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $10.05 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alphonse Zieman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.